What are the ICD-10 guidelines for prostate-derived factors?

ICD-10 guidelines for prostate-derived factors involve coding prostate cancer with PDEF involvement using C61, and documenting PDEF expression and ER status.

How does PDEF affect prostate cancer coding?

PDEF affects prostate cancer coding by requiring documentation of its expression and linking it to codes like C61 and Z17.2 for accurate representation.

ICD-10 Coding for Prostate-Derived Factor Biomarkers(C61, R97.21, D49.5)

Save

Explore comprehensive ICD-10 guidelines for coding prostate-derived factor biomarkers, including PDEF, in prostate cancer cases. Learn about documentation requirements and coding strategies.

Also known as:

PDEFProstate-Derived Ets Transcription FactorPrDGF

Related ICD-10 Code Ranges

Complete code families applicable to Prostate-Derived Factor Biomarkers

C00-D49Primary Range

Neoplasms

→

Code Comparison: When to Use Each Code

Compare key differences between these codes to ensure accurate selection

Code	Description	When to Use	Key Documentation
C61	Malignant neoplasm of prostate	Use when prostate cancer is confirmed and PDEF is involved.	Histological confirmation of prostate cancer PDEF overexpression documented
R97.21	Rising PSA following treatment for malignant neoplasm of prostate	Use for biochemical recurrence with PDEF activity.	Documented rise in PSA levels post-treatment PDEF expression noted

Primary ICD-10-CM Codes

Malignant neoplasm of prostate

C61Billable

Rising PSA following treatment for malignant neoplasm of prostate

R97.21Billable

Differential Codes

Alternative codes to consider when ruling out similar conditions

Neoplasm of uncertain behavior of prostateD49.5

Use when malignancy is not confirmed.

Encounter for screening for malignant neoplasm of prostateZ12.5

Use for screening, not recurrence.

Documentation & Coding Risks

Avoid these common issues when documenting Prostate-Derived Factor Biomarkers.

Omitting PDEF documentation in prostate cancer cases

Impact

Clinical: Inaccurate treatment planning, Regulatory: Non-compliance with coding standards, Financial: Potential claim denials

Mitigation

Ensure PDEF results are included in all relevant reports, Cross-check documentation before coding

Confusing PDEF with PSA markers

Impact

Reimbursement: Incorrect coding may lead to denied claims., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.

Mitigation

Ensure documentation specifies PDEF involvement in malignancy.

Biomarker Documentation

Impact

Failure to document PDEF can lead to audit issues.

Mitigation

Implement standardized documentation templates for PDEF.

Frequently Asked Questions

Documentation requirements, coding pitfalls and FAQs for conditions coded with C61.

Primary Code

C61

Malignant neoplasm of prostate

Quick Navigation

ICD-10 codes5

Coding risks3

FAQs2

ICD-10 Coding for Prostate-Derived Factor Biomarkers(C61, R97.21, D49.5)

Documentation & Coding Risks

Frequently Asked Questions

What are the ICD-10 guidelines for prostate-derived factors?

How does PDEF affect prostate cancer coding?

Related condition guides